Novartis at ASH
Novartis 2020 ASH Annual Meeting Virtual PortalNovartis presence at ASH: …
Entries by English RSS Feed
Meet Novartis Management 2020
This annual event gives investors and industry analysts an opportunity to meet with Novartis executives who share deep insights into the company’s growth, pipeline and strategy.We have delivered strong operational performance over the last three years …
Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event
Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographiesKey growth drivers now contributing to 48% of Innovative Medicines sales; up…
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other indicationsAddition of remestemcel-L could expand Novartis res…
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIsELARA results for Kymriah® in relapsed or refractory (r/r) follicular lymphoma, plus long-term JULI…
Achieving 100% renewable electricity
Novartis signed five virtual power purchase agreements (VPPAs), which are expected to collectively add 277 megawatts of clean power to the electrical grid. This move makes Novartis the first pharmaceutical company set to achieve …
Novartis set to achieve 100% renewable electricity in its European operations
Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical gridProjects expected to address Novartis greenhouse gas emissions across its European operations, equivalent …
Making Possible: Stepping toward a future with cell and gene therapy
Novartis scientist Leila Haery likes to step away from the lab and wander in nature for perspective. While outdoors, the gene therapy expert contemplates the vastness of landscapes and their evolution over time. She’s inspired to ask new questions with…
Leading performance in sustainability
Novartis maitained its strong position in the Dow Jones Sustainability World Index with a percentile score of 91 (vs. 87 in 2019). We are proud of our industry-leading performance in the areas of social and environmental reporting, human capital …
Results from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020
Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD1,2 Follows establishment of multi-disciplinary expert coalition and Novartis commitment to sharing data and findings with ophthalmology co…
